<DOC>
	<DOCNO>NCT01120639</DOCNO>
	<brief_summary>The purpose study investigate safety effectiveness combination treatment glioblastoma multiforme utilize radiotherapy FDA approve chemotherapy drug temozolomide</brief_summary>
	<brief_title>PI/II Temozolomide &amp; Hypofractionated Radiotherapy Tx Supratentorial Glioblastoma Multiform</brief_title>
	<detailed_description>To determine maximum tolerate dose ( MTD ) hypofractionated ( 5 fraction ) radiotherapy temozolomide treatment glioblastoma multiforme , patient evaluate multi-disciplinary team compose radiation oncologist , neurosurgeon , neuro-oncologists assess eligibility . Patient 's oncologic history , present symptom , physical examination , pathology , image study review . Patients evaluate surgical candidacy resectability . Patients surgical candidate undergo surgical resection prior radiotherapy . Patients whose tumor unresectable good surgical candidate undergo biopsy tissue diagnosis . Radiation deliver five fraction .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histopathologically confirm newly diagnose glioblastoma multiforme . Diagnosis must make surgical biopsy excision The tumor must supratentorial location The planning target volume ( tumor plus margin ) must measure &lt; = 150 cm^3 volume Age &gt; =18 year Life expectancy least 12 week Patient must adequate organ function tolerate temozolomide ( detail protocol ) Patients previously treat brain irradiation region would result overlap radiation field Tumor focus detect tentorium Multifocal disease leptomeningeal spread Prior allergic reaction study drug involve protocol Patients pacemaker allow undergo CT instead MRI Pediatric patient ( age &lt; 18 ) , pregnant woman , nurse patient exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>